Table 2.
Overview of all described DENV entry inhibitors.
| Class | Compound | Serotype* | Cell line | References |
|---|---|---|---|---|
| Fusion inhibitors | 1OAN1 | DENV-2 | LLC-MK2 | [49] |
| DN59 | DENV-2 | LLC-MK2 | [50] | |
| Compound 6 | DENV-1-4 | A549, BHK | [51] | |
| Tetracycline derivates | DENV-2 | BHK | [52] | |
| Doxorubicin derivate | DENV-1, -2, -3 | Vero, C6/36 | [53] | |
| NITD448 | DENV-2 | BHK, C6/36 | [54] | |
|
| ||||
| Glycosidase inhibitors | Castanospermine | DENV-1-4 | BHK | [55, 56] |
| DENV-2 | Huh-7 | [55] | ||
| DNJ | DENV-1 | Mouse neuro 2a cells | [56] | |
| NN-DNJ | DENV-2 | BHK | [57] | |
| Alkylated iminocyclitol | DENV-2 | BHK | [58] | |
| OSL-9511 | DENV-2 | BHK | [59] | |
| CM-9-78 | DENV-2 | BHK | [60] | |
|
| ||||
| CBAs | Con A, WGA | DENV-2 | BHK | [43] |
| HHA, GNA, UDA | DENV-1-4 | Raji/DC-SIGN, MDDC | [61, 62] | |
| DENV-1-4 | Huh-7, U87/DC-SIGN | Unpublished results | ||
| DENV-1-4 | Raji/L-SIGN, U87/L-SIGN | Unpublished results | ||
| PRM-S | DENV-2 | MDDC | [62] | |
|
| ||||
| Heparan mimetics | GAG | DENV-2 | Vero | [28] |
| Heparin | DENV-2 | Vero | [28, 29] | |
| DENV-2 | BHK | [43] | ||
| DENV-2 | Hepatocytes | [38] | ||
| Suramin | DENV-2 | Vero, BHK | [28, 63] | |
| PI-88 | DENV-2 | BHK and in mice | [63] | |
| PPS | DENV-2 | BHK | [63] | |
| Fucoidan | DENV-2 | BHK | [64] | |
| Sulfated galactomannan | DENV-1 | C6/36 | [65] | |
| DL-galactan | DENV-2, -3 | Vero, HepG2 | [66] | |
| Carrageenan | DENV-2, -3 | Vero, HepG2 | [66, 67] | |
| α-D-glucan | DENV-2 | BHK | [68] | |
| Dextran sulfate 8000 | DENV-2 | Hepatocytes, Vero | [66] | |
| DS (MW > 500,000 Da) | DENV-2 | Raji/DC-SIGN | [61] | |
| Zosteric acid | DENV-1-4 | LLC-MK2 | [69] | |
*Serotype: The serotype mentioned is the serotype that has been tested and found susceptible to inhibition by the compound. Non-mentioned serotypes were not tested or could not be inhibited by the compound.